The FDA expands approval of Skyrizi (risankizumab-rzaa) for pediatric patients aged 6 years and older with moderate to severe plaque psoriasis or active psoriatic arthritis.
The new presentation is expected to provide an additional self-administration option for patients with polycythemia vera.
AbbVie Inc. (NYSE:ABBV) will trade ex-dividend on July 15, putting it among the 10 Best July Dividend Stocks to Buy. On June ...
On Friday, the U.S. Food and Drug Administration (FDA) approved AbbVie Inc.’s ABBV SKYRIZI (risankizumab-rzaa) for children ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results